Evaluating the safety and efficacy of propranolol administration in preterm newborns suffering from a precocious phase of retinopathy of prematurity (ROP): A randomised controlled trial

A. Meyer University Children's Hospital (Italy)0 个研究点目标入组 44 人开始时间: 2010年7月12日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•The studied population consists of preterm infants delivered at less than 32 weeks gestational age admitted to the Neonatal Intensive Care Unit at the A. Meyer University Children's Hospital, Florence and at the Institute of Pediatrics and Neonatology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan.
•1. Infants who have been screened for ROP (=32 weeks gestation) who developed zone II-III, stage 2 ROP without plus.
•2. Informed Consent from a parent

•1. Newborns with congenital cardiovascular anomalies, renal failure, cerebral haemorrhage, which contraindicate the use of beta-blockers
•2. Newborns with ROP stages more advances than zone II-III, stage 2 ROP without plus
•3. Informed Consent from a parent refused. This will mean that an infant automatically will receive standard laser therapy. No data will be used from an infant without Informed Consent.

发起方

A. Meyer University Children's Hospital (Italy)